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TWO CASE HISTORIES AND REVIEW
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Abstract
Liposarcoma of the thyroid gland is rare with only 3 cases reported in the English literature. We present a further two patients
whom we have recently treated: a 49 year old lady with a myxoid liposarcoma and a 71 year old man with a pleomorphic
liposarcoma. Both underwent macroscopic excision of tumour but had positive margins, so were then treated with external
beam radiotherapy. The former patient died from metastases 10 months after presentation, the latter remains alive but has
developed metastatic disease on follow up at 24 months.
We recommend the use of high dose radiotherapy following radical surgery as margins of excision are usually narrow in
this most difficult region. The role of chemotherapy is yet to be established.
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Introduction
Cancer of the thyroid gland is rare, accounting for
only 1% of all malignancies. Classified as either
epithelial or non-epithelial, the majority are of
papillary and follicular cell origin, accounting for
95%. Non-epithelial tumours include malignant
lymphoma and tumours arising from mesenchymal
elements.
1 Our literature search using MEDLINE
limited to publications in English, revealed less than
50 primary sarcomas of the thyroid. There have been
a few reports of sarcoma metastasising to the thyroid
gland (‘‘unpublished observations’’).
Liposarcoma of the thyroid gland is extremely
rare. We found three cases in the English reported
literature, one of which was radiation induced. We
present a further two cases and discuss the ideal
management of this uncommon condition.
Case History 1
A 49-year-old Greek Cypriot woman presented with
a one-year history of an enlarging swelling in her
neck, associated with 3 months increasing shortness
of breath and dysphagia. She had a large, fixed, hard
mass in the thyroid gland with retrosternal extension.
Fifteen years earlier, she had undergone a partial
thyroidectomy for a multi-nodular goitre but this
histology was not available for review.
Tru-cut biopsy gave the diagnosis of myxoid
liposarcoma. Computerised tomography scan
revealed a 7cm mixed attenuation soft tissue mass
within the right lobe of the thyroid, displacing and
compressing both trachea and oesophagus. The mass
appeared inseparable from the right carotid artery
and internal jugular vein, encasing the carotid artery
and extending through the thoracic inlet to the origin
of the right main bronchus (Fig. 1). The patient
deteriorated developing neck pain and stridor.
Bronchoscopy showed the right vocal cord was not
functioning. There was severe compression of the
trachea along its entire length, narrowing its lumen
to a crescent. At surgery, there was a multinodular
mass in the right lobe of the thyroid, measuring
1275cm, adherent to the wall of the trachea and
infiltrating the pharyngeal muscle. Following divi-
sion of the strap muscles and the right recurrent
laryngeal nerve, resection of the tumour was macro-
scopically complete.
Histological examination demonstrated a malig-
nant neoplasm diffusely infiltrating the thyroid
parenchyma, adjacent soft tissues and skeletal
muscle. The tumour comprised a mixture of ele-
ments ranging from highly pleomorphic giant cells to
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nuclei. The highest mitotic rate was 10 per 10hpf,
EORTC grade 2. The stroma was markedly myxoid
and there was an arborising capillary vasculature.
Tumour extended to the resection margins.
Four weeks following surgery, external beam
radiotherapy to the neck and superior mediastinum
completed treatment. This comprised a two-phase
technique. Anterior and undercouched fields cov-
ered both sides of the neck and superior media-
stinum in phase 1 to a dose of 28Gy in 14 fractions
treated daily. Phase 2 encompassed the tumour bed
and received 30Gy in 15 fractions daily, to a CT
planned volume. During treatment, the patient
developed a chest infection and experienced oesoph-
agitis requiring a short admission, causing reduction
of the phase 1 dose and extension of the total
treatment time.
She remained well until 7 months after radio-
therapy when she developed subcutaneous nodules
in her scalp, weight loss and abdominal pain. The
primary site remained free of disease. CT scan
revealed lung and liver metastases. She received
single agent doxorubicin at 60mg/m
2. The liver
disease progressed after one cycle and Ifosfamide
at 2.5g/m
2 was substituted. After one cycle, she
developed renal failure. Further chemotherapy
would have been inappropriate and she returned to
Cyprus where she died 10 months after her original
presentation.
Case History 2
A 71-year-old retired man presented with a one-
month history of difficulty in breathing, a feeling of
constriction in his neck and hoarseness of the voice.
These symptoms progressed to marked dysphagia
and deafness in the left ear.
On examination, he had mild stridor and a left
secretory otitis media. Endoscopic examination of
his posterior nasal space was unremarkable.
Palpation of his neck revealed a firm mass above
the sternal notch, more prominent to the left of the
midline, which did not move on swallowing. There
was no lymphadenopathy and flexible laryngoscopy
showed both vocal cords to be mobile. Computerised
tomography scan confirmed a mass arising from the
left lobe of the thyroid, extending from the thoracic
inlet behind the brachiocephalic vein to the level of
the aortic arch.
His symptoms progressed rapidly although ste-
roids relieved the stridor. Fine needle aspiration
cytology was not diagnostic. Open thyroid biopsy
was undertaken and the middle ear effusion drained.
The thyroid tissue was slightly nodular with mild
variation in follicle size; there was mild focal
inflammation in the capsule, but no features of
malignancy. A biopsy taken from the left side of the
post-nasal space showed a moderate chronic inflam-
matory infiltrate, but no features of malignancy.
Surgical exploration was required to relieve the
tracheal compression. Bronchoscopy revealed an
oedematous larynx and severe compression of the
cervical and upper thoracic trachea. Tissues of the
neck were compressed and the oesophagus was
adherent to the tumour. After division of the strap
muscles, the medial aspect of the gland was
mobilised and left hemi-thyroidectomy was carried
out. Excision was macroscopically complete.
Histology confirmed a pleomorphic liposarcoma
extending to the margins of excision (Fig. 2).
Post-operative recovery was complicated by the
Fig. 1. Computerised tomography scan showing a mixed attenuation soft tissue mass within the right lobe of the thyroid.
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prescribed replacement thyroxine and CT scan
excluded pulmonary metastases.
Radical dose radiotherapy completed his treat-
ment. Phase 1 utilised anterior and undercouched
fields encompassing both sides of the neck and
superior mediastinum, delivering a mid-plane dose
of 46Gy in 23 daily fractions. Phase 2 encompassed
the original tumour volume to 14Gy in 7 fractions,
bringing the total dose to 60Gy over 6 weeks.
Follow up at 11 months found him asymp-
tomatic with no evidence of local recurrence but
routine chest x-ray revealed multiple and bilateral
unresectable lung metastases. Single agent doxo-
rubicin, 60mg/m
2, was given for 3 cycles with the
second complicated by admission for neutropenic
sepsis. In the absence of response no further
chemotherapy was administered. He remains
asymptomatic from his lung disease 14 months
after their diagnosis but has developed bone
metastases; right acetabular involvement requiring
palliative radiotherapy.
Discussion
Liposarcoma forms a subset of the rare diagnosis
of non-epithelial thyroid malignancies. Other
types include primary thyroid lymphoma, forming
2% of extra-nodal lymphomas, malignant teratoma
and primary squamous cell carcinoma.
2 Isolated
case reports of thyroid sarcoma exist and include
fibrosarcoma, leiomyosarcoma, osteosarcoma,
chondrosarcoma and malignant diffuse haemangio-
pericytoma.
3 There are also reports of liposarcoma
metastasing to the thyroid gland.
The peak incidence of liposarcoma, the second
commonest variety of soft tissue sarcoma, is in the
5th and 6th decades and classically occurs in the
extremities and retroperitoneum. With a male pre-
dominance, its aetiology and pathogenesis are
unknown. It is classified into well-differentiated,
myxoid, round cell, pleomorphic and dedifferen-
tiated types. The well-differentiated type is relatively
indolent and has a high rate of local recurrence
but rarely metastasises. The myxoid and round cell
types are slightly more aggressive. These types have
a 75–100% 5-year survival. Pleomorphic cell types
have a higher rate of local recurrence and are more
likely to result in distant metastases, with a five-year
survival of 20%. The dedifferentiated type contains
both the well-differentiated type and a non-lipogenic
sarcoma resembling a malignant fibrous histiocy-
toma or a pleomorphic fibrosarcoma. Behaviour
probably depends on the amount of dedifferentia-
tion.
4,5
Undifferentiated (anaplastic) carcinomas of the
thyroid resemble sarcomas to such a degree that
differential diagnosis is at best difficult and some-
times impossible. Most malignant thyroid tumours
with a sarcoma-like appearance show signs of
epithelial differentiation by morphologic or immu-
nohistochemical criteria and are therefore classified
as undifferentiated carcinoma. As undifferentiated
thyroid carcinomas are exceptionally rare before the
Fig. 2. Pleomorphic liposarcoma.
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tumour actually being a true sarcoma increases as the
patient’s age decreases.
6
Lipoblasts do not necessarily indicate a diagnosis
of liposarcoma. They are often found in myxoid
and sclerosing liposarcomas but are not essential
for these two diagnoses. They are however essential
for the diagnosis of the pleomorphic and round cell
liposarcoma. Immunohistochemistry staining posi-
tive for S100 protein may be helpful in differentiating
a true sarcoma although if strongly positive; may be
suggestive of melanoma or epitheloid malignant
peripheral nerve sheath tumour. CD68 can be
positive in some liposarcomas.
7
We have presented the fourth and fifth cases
of thyroid liposarcoma in the English reported
literature. The first was a 56-year-old woman with
a myxoid liposarcoma and a history of goitre.
She initially refused surgery but consented on
developing dyspnoea. Her condition deteriorated
post-operatively and she died 2 months later of
an unspecified cause.
3 The second described an
elderly man who, three years after the diagnosis of
a presumed thyroid adenoma, developed hoarseness
and dysphagia as the thyroid rapidly enlarged. There
was no post-operative treatment following removal
of a well-differentiated thyroid liposarcoma and he
died 2 years later from pneumonia unrelated to
disease progression.
8 The third, was a case of a
radiation induced myxoid liposarcoma in a 23-year-
old man, who presented 12 years after receiving high
dose radiotherapy for a T2N1 lymphoepithelioma of
the nasopharynx. After surgery and brachytherapy,
he remained well on follow up at 22 months.
9
As with sarcomas at any site, surgery remains the
definitive and potentially curative treatment. The
likelihood of microscopic disease invading surround-
ing tissuesand the possibility of skip lesionsmean that
wide margins are required for adequate resection.
This is impossible in thyroid sarcomas and in head
and neck sarcomas in general, since at presentation
the majority of tumours have extended beyond the
capsule and lie in close proximity to vital structures.
Wide functional resection remains the objective.
Referral to specialist sarcoma unit and detailed
pre-operative imaging permits the probability of
maximal resection of the tumour at the first opera-
tion. If in the rare circumstances where surgery has
not been maximally cytoreductive, we would recom-
mend further resection if operable macroscopic
disease remains. For thyroid sarcoma, total, or near
total thyroidectomy would be ideal. However, as in
our second case, it may not be worth second
operation to total thyroidectomy in the event of
complete macroscopic excision.
Survival in head and neck sarcomas is less than
that of limb sarcomas and local recurrence is more
frequent. A series of 130 head and neck sarcomas
treated at the Royal Marsden Hospital showed an
overall 5-year survival of only 50%. Results with
surgery alone were poor as were those with radio-
therapy as sole treatment. Surgery with radiotherapy,
however, improved survival.
10 Radiotherapy is
recommended pre- or post-operatively in curative
management.
The use of radiotherapy alone in thyroid lipo-
sarcoma is not recommended except for cases where
poor patient performance status precludes surgery.
The relative radioresistance of these tumours
demands high dose. Even if only palliation of poten-
tial fungation or haemorrhage is the aim. As our
second case shows, in the presence of indolent
disease, local control is of paramount importance.
Patients may succumb to metastatic disease before
local recurrence develops.
Vital structures adjacent to the thyroid mean a
high degree of precision is required. With conven-
tional radiotherapy, a shrinking field technique is
used to minimise the high dose volume. As for
sarcomas at other sites, the phase 1 volume should
encompass all planes of potential tumour spread. As
nodal spread is not a feature, encompassing neck
nodes is not necessary. Phase 1 should receive a dose
of 46Gy in 2Gy daily fractions, to remain within
spinal cord tolerance, with margins of 5cm around
the original gross tumour volume. Phase 2 delivers
an additional 14Gy in 2Gy daily fractions, with a
margin of 2cm, avoiding spinal cord. The phase 2
volume is CT planned with a multi-leaf collimator
and requires a perspex shell for accurate positioning.
A third phase can be given to 66Gy if positive
margins are documented.
Early radiation oesophagitis though transient may
lead a poor tolerance of higher doses of radiation.
Late radiation morbidity also manifesting as dys-
phagia precludes a dose of greater than 60Gy in
most situations. Failure to complete the primary
peristaltic wave has been demonstrated by dynamic
studies after doses of 45–60Gy.
11 When compared
to conventional radiotherapy, three-dimensional
conformal radiotherapy enables a reduction of the
amount of normal tissue irradiated and thus
complications of dysphagia and myelitis, although
care should be taken to ensure adequate coverage
of the tumour volume. The advent of Intensity
Modulated Radiotherapy (IMRT) may allow
reduced normal tissue damage, along with improved
coverage of the planned target volume and dose
escalation is theoretically possible but will still be
limited by oesophageal tolerance.
12
The energy range should be between 4 and 8
mega-volt photons. A direct electron beam may be
used for the last few fractions of radiotherapy but is
usually sub-optimal for delivering the greater part
of the dose, which should be given by at least two,
possibly three, complementary fields. The whole
length of the scar should lie within the phase 1
volume. Recurrence is more likely to occur at depth
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the maximum dose to the surface.
13
As radiotherapy is often a crucial component in the
effective treatment of sarcoma, ways of increasing
therapeuticgainhavebeeninvestigated.Pre-operative
radiotherapy was compared to post-operative radio-
therapy at the Princess Margaret Hospital. Their
randomised trial showed an increase in wound
complications in the pre-operative group.
14 There
are no randomised trials comparing survival,
although Suit et al. did show benefit in local
control in one series of patients published in 1981.
15
Other more recent trials have shown no benefit.
16
We recommend surgery first, wherever possible, as
definitive treatment. No significant improvement in
overall results has been observed with brachytherapy
over conventional external beam radiotherapy.
16
Hyperfractionated radiotherapy with the aim of
delivering a higher total dose of radiation without an
increase in late normal tissue damage has shown to be
a feasible regime with comparable local control rates.
Randomised studies comparing it to conventional
treatment are awaited.
17
Chemotherapy for sarcoma is indicated for symp-
tomatic disease that may be either metastatic or
recurrent tumour at the primary site in patients
previously treated by maximal surgery and radio-
therapy. In high risk patients it can be used as
adjuvant or neoadjuvant treatment but this is not
yet of proven survival benefit. A few studies show
an improvement in local recurrence rates. A meta-
analysis of 14 trials of doxorubicin-based chemo-
therapy published in 1997 had a median follow up
of 9.4 years and showed a significantly improved
time to local and distant recurrence. Overall survival
whilst improving at 10 years from 50–54% was not
statistically significant.
18 The largest single study of
adjuvant chemotherapy in soft tissue sarcoma was
performed by the European organisation for research
and treatment of cancer.
19 468 patients were treated
with surgery for their primary sarcoma, and with
adjuvant radiation used for margins less than 1cm.
Patients were randomised to receive or not receive
combination chemotherapy with cyclophosphamide,
vincristine, doxorubicin and dacarbazine given every
28 days for 8 cycles. Disease free survival and local
control were both better in the chemotherapy arm
but overall survival was not significantly different
between the 2 arms. The accrual time, however,
was 11years and nearly half the patients were unable
to complete the chemotherapy. A relatively large
number of patients were ineligible for analysis,
most commonly due to inappropriate radiotherapy.
Few cytotoxic agents are active for the treatment
of soft tissue sarcomas. Those with activity include
doxorubicin, singly or in combination with ifosfa-
mide and occasionally dacarbazine. Response rates
are in the region of 20%.
20,21 Partial response is often
of short duration, toxicity is always severe and overall
survival is poor. Use is generally confined to patients
with symptomatic disease that is not amenable to
surgery or radiotherapy.
In conclusion, we present the fourth and fifth cases
of thyroid liposarcoma. The principles of treatment
are the same as those of soft tissue sarcoma at other
sites, in that complete surgical resection provides
the best outcome. Narrow margins demand radical
dose radiotherapy to maximise local control. The role
of chemotherapy is not fully established but usually
confined to the metastatic setting.
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